Madrigal Pharmaceuticals (MDGL) Form 4 SYNTA PHARMACEUTICALS / Keith R Gollust ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Gollust Keith R

(Last) (First) (Middle)

C/O SYNTA PHARMACEUTICALS CORP.

45 HARTWELL AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SYNTA PHARMACEUTICALS CORP [ SNTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2015

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2015		A		22,727(1)	A	$0(1)	374,493	D
Common Stock	07/01/2015		A		13,636(2)	A	$0(2)	388,129	D
Common Stock	07/01/2015		A		4,545(3)	A	$0(3)	392,674	D
Common Stock	07/01/2015		A		4,545(4)	A	$0(4)	397,219	D
Common Stock	07/01/2015		A		4,545(5)	A	$0(5)	401,764	D
Common Stock								3,173,383	I	By Wyandanch Partners, L.P.(6)
Common Stock								175,000	I	By Keith R. Gollust IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$2.2	07/01/2015		A		20,000		(7)	07/01/2025	Common Stock	20,000	$0	20,000	D
Director Stock Option (Right to Buy)	$2.2	07/01/2015		A		15,000		(8)	07/01/2025	Common Stock	15,000	$0	15,000	D

Explanation of Responses:

1. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as a director of the Issuer on such date.

2. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as Chairman of the Board of Directors of the Issuer on such date.

3. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as Chairman of the Nominating and Governance Committee of the Board of Directors of the Issuer on such date.

4. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as a member of the Audit Committee of the Board of Directors of the Issuer on such date.

5. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as a member of the Compensation Committee of the Board of Directors of the Issuer on such date.

6. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

7. The option vests as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as a director of the Issuer on such date.

8. The option vests as to 25% of the shares on each of September 30, 2015, December 31, 2015, March 31, 2016 and June 30, 2016, provided the Reporting Person continues to serve as Chairman of the Board of Directors of the Issuer on such date.

	/s/ Garrett M. Winslow, Attorney-in-Fact	07/06/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.